DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its investigator-blinded study comparing the safety and efficacy of EpiCeram® Skin Barrier Emulsion to that of Elidel® Cream (pimecrolimus 1%), a standard non-steroidal therapy in the treatment of mild-to-moderate pediatric atopic dermatitis (AD).
